​

Autolus Therapeutics (AUTL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AUTL Stock Forecast

Autolus Therapeutics (AUTL) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $7.60, with a high of $7.60 and a low of $7.60. This represents a 256.81% increase from the last price of $2.13.

$2 $3 $4 $5 $6 $7 $8 High: $7.6 Avg: $7.6 Low: $7.6 Last Closed Price: $2.13

AUTL Stock Rating

Autolus Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

AUTL Price Target Upside V Benchmarks

TypeNameUpside
StockAutolus Therapeutics256.81%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$7.60$9.15
Last Closing Price$2.13$2.13$2.13
Upside/Downside-256.81%329.58%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2528---10
Jan, 2528---10
Dec, 2428---10
Nov, 24282--12
Oct, 24472--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 18, 2024Graig SuvannavejhGoldman Sachs$7.60$3.03150.83%256.81%
May 20, 2024Yanan ZhuWells Fargo$8.00$4.3982.23%275.59%
Apr 08, 2024Asthika GoonewardeneTruist Financial$11.00$5.5398.92%416.43%
Mar 15, 2024Asthika GoonewardeneTruist Financial$10.00$5.8271.82%369.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024Goldman SachsBuyupgrade
Jun 17, 2024NeedhamBuyBuyhold
May 20, 2024Wells FargoOverweightOverweighthold
Mar 18, 2024NeedhamBuyBuyhold
Mar 08, 2023Piper SandlerBuyBuyhold
Dec 09, 2022NeedhamBuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 $1 $2 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.76$-1.97$-1.57$-1.20-----
Avg Forecast$-2.67$-1.82$-1.58$-1.01$-0.90$-0.80$-0.59$-0.11$0.57
High Forecast$-6.09$-4.16$-3.68$-1.05$-1.05$-0.98$-0.99$-1.01$0.16
Low Forecast$-0.77$-0.53$-0.42$-0.99$-0.74$-0.57$-0.01$0.95$1.33
Surprise %3.37%8.24%-0.63%18.81%-----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$242.00K$2.33M$6.19M$1.70M-----
Avg Forecast$1.55M$12.19M$13.54M$1.95M$15.66M$65.37M$157.78M$353.82M$578.70M
High Forecast$703.74K$5.52M$5.90M$1.89M$15.51M$32.66M$69.39M$155.61M$254.50M
Low Forecast$3.09M$24.21M$27.41M$2.12M$15.83M$115.86M$318.41M$714.03M$1.17B
Surprise %-84.43%-80.88%-54.26%-12.91%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-142.09M$-142.10M$-148.84M$-208.38M-----
Avg Forecast$-463.84M$-316.78M$-132.43M$-208.38M$-155.10M$-135.06M$-145.36M$-29.27M$99.35M
High Forecast$-1.06B$-723.04M$-158.92M$-250.06M$-181.79M$-170.89M$-171.63M$-175.31M$27.00M
Low Forecast$-133.79M$-91.38M$-105.95M$-166.71M$-128.42M$-99.23M$-1.82M$164.84M$230.84M
Surprise %-69.37%-55.14%12.39%------

AUTL Forecast FAQ

Is Autolus Therapeutics stock a buy?

Autolus Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Autolus Therapeutics is a favorable investment for most analysts.

What is Autolus Therapeutics's price target?

Autolus Therapeutics's price target, set by 4 Wall Street analysts, averages $7.6 over the next 12 months. The price target range spans from $7.6 at the low end to $7.6 at the high end, suggesting a potential 256.81% change from the previous closing price of $2.13.

How does Autolus Therapeutics stock forecast compare to its benchmarks?

Autolus Therapeutics's stock forecast shows a 256.81% upside, outperforming the average forecast for the healthcare stocks sector (25.00%) and outperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Autolus Therapeutics over the past three months?

  • February 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Autolus Therapeutics’s EPS forecast?

Autolus Therapeutics's average annual EPS forecast for its fiscal year ending in December is $-0.9 for 2024, a -25.00% decrease from the reported $-1.2 in 2023. The prediction for 2025 is $-0.8, $-0.59 for 2026, $-0.11 for 2027, and $0.57 for 2028.

What is Autolus Therapeutics’s revenue forecast?

Autolus Therapeutics's average annual revenue forecast for its fiscal year ending in December is $15.66M for 2024, a 822.20% increase from the reported $1.7M in 2023. The forecast for 2025 is $65.37M, $157.78M for 2026, $353.82M for 2027, and $578.7M for 2028.

What is Autolus Therapeutics’s net income forecast?

For its fiscal year ending in December, Autolus Therapeutics's average annual net income forecast is $-155M for 2024, reflecting a -25.57% decrease from the reported $-208M in 2023. The projection for 2025 is $-135M, $-145M for 2026, $-29.269M for 2027, and $99.35M for 2028.